Clinical Edge Journal Scan

Age at disease onset influences disease characteristics in PsA


 

Key clinical point: Age at onset of psoriatic arthritis (PsA) influences disease characteristics, with individuals developing PsA at older age having worse functionality and greater structural damage but a lower frequency of enthesitis and dactylitis.

Major finding: Patients with late vs early onset PsA showed greater structural damage (odds ratio [OR] 3.3; 95% CI 1.3-8.1), higher frequency of arthritis in upper limbs (OR 2.8; 95% CI 1.0-7.7), greater loss of functionality (OR 1.3; 95% CI 1.0-1.6), and lower frequency of enthesitis (OR 0.1; 95% CI 0-0.5) and sacroiliitis (OR 0.06; 95% CI 0-0.5).

Study details: This observational cross-sectional study included 231 patients with PsA with <10 years of disease duration from the REGISPONSER and RESPONDIA registries who were categorized into the early onset (≤40 years) or late onset (≥60 years) group depending on age at PsA symptom onset.

Disclosures: This study did not report the source of funding. The authors declared no conflicts of interest.

Source: Puche-Larrubia MÁ et al. Differences between early vs late-onset of psoriatic arthritis: Data from the respondia and regisponser registries. Joint Bone Spine. 2023;105563 (Mar 17). Doi: 10.1016/j.jbspin.2023.105563

Recommended Reading

Concurrent onset of skin and joint symptoms tied to high disease activity in PsA
Psoriatic Arthritis ICYMI
Apremilast safe and effective in biologic-naive patients with early PsA
Psoriatic Arthritis ICYMI
Disease burden is higher in women vs men with psoriatic arthritis
Psoriatic Arthritis ICYMI
Commentary: Disease activity, JAK inhibitors, and pregnancy risks in PsA, April 2023
Psoriatic Arthritis ICYMI
Does COVID-19 vaccination worsen disease activity in PsA patients on targeted therapy?
Psoriatic Arthritis ICYMI
Sex-based differences in efficacy and safety of tofacitinib in PsA
Psoriatic Arthritis ICYMI
Real-life study confirms benefits of secukinumab in PsA
Psoriatic Arthritis ICYMI
Triglyceride-glucose index: A promising atherosclerotic marker in PsA
Psoriatic Arthritis ICYMI
Distinct clinical manifestations of PsA with axial involvement and axial spondyloarthritis with psoriasis
Psoriatic Arthritis ICYMI
Vitamin D deficiency associated with lowest retention rates of first bDMARD in PsA
Psoriatic Arthritis ICYMI